Aveo On­col­o­gy gets the long-await­ed green­light to mar­ket tivozanib — 9 years af­ter fil­ing its first NDA

Sev­en years af­ter Aveo On­col­o­gy’s tivozanib was sub­ject­ed to a scathing dress­down by the FDA’s can­cer czar Richard Paz­dur — fol­lowed by a swift re­jec­tion and a bump­ing road to­ward re­fil­ing — the ty­ro­sine ki­nase in­hibitor has been ap­proved for re­lapsed or re­frac­to­ry ad­vanced re­nal cell car­ci­no­ma. Known for over a decade as ti­vo, the drug will now be mar­ket­ed as Fo­tiv­da.

It was a much nar­row­er la­bel than what they had ini­tial­ly sought, but the ap­proval marked the best news the Boston biotech has put out in years. Share shot up 89.11% to $15.28 soon af­ter the an­nounce­ment hit the wires, and then some more in af­ter-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER